Skip to main content
SpringerLink
Log in

Polycystic Ovary Syndrome

  • Chapter
  • First Online:
Clinical Reproductive Medicine and Surgery

  • 2090 Accesses

Abstract

Polycystic ovary syndrome (PCOS) refers to a complex, multidimensional disorder resulting in defects in reproduction and metabolism. Although one of the primary characteristic of PCOS is the presence of multiple cysts on the ovaries, the complexity of the syndrome is reflected in the wide range of its clinical manifestations, most notably insulin resistance (50 %), obesity (70 %), irregular menses (80 %), and signs of hyperandrogenism (80 %), such as hirsutism and acne.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 159.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 209.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. Polycystic ovary syndrome. Boston: Blackwell Scientific; 1992. p. 377–84.

    Google Scholar 

  2. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19–25.

    Article  Google Scholar 

  3. Polson DW, Adams J, Wadsworth J, Franks S. Polycystic ovaries—a common finding in normal women. Lancet. 1988;1(8590):870–2.

    Article  PubMed  CAS  Google Scholar 

  4. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeast United States: a prospective study. J Clin Endocrinol Metab. 1998;83(9):3078–82.

    Article  PubMed  CAS  Google Scholar 

  5. O’Driscoll J, Mamtora H, Higginson J, Pollock A, Kane J, Anderson D. A prospective study of the prevalence of clear-cut endocrine disorders and polycystic ovaries in 350 patients presenting with hirsutism or androgenic alopecia. Clin Endocrinol. 1994;41:231–6.

    Article  Google Scholar 

  6. Hatch R, Rosenfield R, Kim M, Tredway D. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol. 1981;140: 815–30.

    PubMed  CAS  Google Scholar 

  7. Betti R, Bencini P, Lodi A, Urbani C, Chirelli G, Crosti C. Incidence of polycystic ovaries in patients with late-onset or persistent acne: hormonal reports. Dermatologica. 1990;181:109–11.

    Article  PubMed  CAS  Google Scholar 

  8. Cela E, Robertson C, Rush K, Kousta E, White DM, Wilson H, et al. Prevalence of polycystic ovaries in women with androgenic alopecia. Eur J Endocrinol. 2003;149:439–42.

    Article  PubMed  CAS  Google Scholar 

  9. Carmina E, Lobo R. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab. 1999;84(6):1897–9.

    Article  PubMed  CAS  Google Scholar 

  10. Dunaif A, Graf M. Insulin administration alters gonadal steroid metabolism independent of changes in gonadotropin secretion in insulin-resistant women with the polycystic ovary syndrome. J Clin Invest. 1989;83:23–9.

    Article  PubMed  CAS  Google Scholar 

  11. Arner P. Control of lipolysis and its relevance to development of obesity in man. Diabetes Metab Rev. 1988;4:507–15.

    Article  PubMed  CAS  Google Scholar 

  12. Barbieri R, Ryan K. Hyperandrogenism, insulin resistance and acanthosis nigricans syndrome: a common endocrinopathy with distinct pathophysiologic features. Am J Obstet Gynecol. 1983;147:90–101.

    PubMed  CAS  Google Scholar 

  13. Sagle M, Bishop K, Ridley N. Recurrent early miscarriage and polycystic ovaries. BMJ. 1988;297:1027–8.

    Article  PubMed  CAS  Google Scholar 

  14. Gray R, Wu L. Subfertility and risk of spontaneous abortion. Am J Public Health. 2000;90(9):1452–4.

    Article  PubMed  CAS  Google Scholar 

  15. Regan L, Braude P, Trembath P. Influence of past reproductive performance on risk of spontaneous abortion. BMJ. 1989;299:541–5.

    Article  PubMed  CAS  Google Scholar 

  16. Liddell H, Sowden K, Farquhar CM. Recurrent miscarriage: screening for polycystic ovaries and subsequent pregnancy outcome. Aust N Z J Obstet Gynaecol. 1997;37(4):402–6.

    Article  PubMed  CAS  Google Scholar 

  17. Clifford K, Rai R, Watson H, Regan L. An informative protocol for the investigation of recurrent miscarriage: preliminary experience of 500 consecutive cases. Hum Reprod. 1994;9(7):1328–32.

    PubMed  CAS  Google Scholar 

  18. Homburg R, Armar N, Eshel A, Adams J, Jacobs H. Influence of serum luteinising hormone concentrations on ovulation conception, and early pregnancy loss in polycystic ovary syndrome. BMJ. 1988;297(1024):1026.

    Google Scholar 

  19. Yen SS, Vela P, Rankin J. Inappropriate secretion of follicle-stimulating hormone and luteinizing hormone in polycystic ovary disease. J Clin Endocrinol Metab. 1970;30:435–42.

    Article  PubMed  CAS  Google Scholar 

  20. Berga S, Guzick D, Winters S. Increased luteinizing hormone and a-subunit secretion in women with hyperandrogenic anovulation. J Clin Endocrinol Metab. 1993;77(4):895–901.

    Article  PubMed  CAS  Google Scholar 

  21. Morales A, Laughlin GA, Butzow T, Maheshwari H, Baumann G, Yen SS. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J Clin Endocrinol Metab. 1996;81:2854–64.

    Article  PubMed  CAS  Google Scholar 

  22. Hayes F, Taylor A, Martin K, Hall J. Use of a gonadotropin-releasing hormone antagonist as a physiologic probe in polycystic ovary syndrome: assessment of neuroendocrine and androgen dynamics. J Clin Endocrinol Metab. 1998;83(7):2343–9.

    Article  PubMed  CAS  Google Scholar 

  23. Knobil E. Neuroendocrine control of the menstrual cycle. Recent Prog Horm Res. 1980;36:53.

    PubMed  CAS  Google Scholar 

  24. Rasmussen DD, Gambacciani M, Swartz W, Tueros VS, Yen SS. Pulsatile gonadotropin-releasing hormone release from the human medibasal hypothalamus in vitro: opiate receptor-mediated suppression. Neuroendocrinology. 1989;49:150.

    Article  PubMed  CAS  Google Scholar 

  25. Prevot V, Croix D, Bouret S, Dutoit S, Tramu G, Stefano GB, et al. Definitive evidence for the existence of morphological plasticity in the external zone of the median eminence during the rat estrous cycle: implication of neuro-glio-endothelial interactions in gonadotropin-releasing hormone release. Neuroscience. 1999;94:809–19.

    Article  PubMed  CAS  Google Scholar 

  26. Daniels T, Berga S. Resistance of gonadotropin releasing hormone drive to sex steroid-induced suppression in hyperandrogenic anovulation. J Clin Endocrinol Metab. 1997;82(12):4179–83.

    Article  PubMed  CAS  Google Scholar 

  27. Kalro BN, Loucks TL, Berga SL. Neuromodulation in polycystic ovary syndrome. Obstet Gynecol Clin North Am. 2003;14:529–55.

    Google Scholar 

  28. Kamberi IA, Mical RS, Porter JC. Hypophysial portal vessel infusion: in vivo demonstration of LRF, FRF, and PIF in pituitary stalk plasma. Endocrinology. 1971;89:1042–6.

    Article  PubMed  CAS  Google Scholar 

  29. Findell PR, Wong KH, Jackman JK, Daniels DV. B1-Adrenergic and dopamine (D1)-receptors coupled to adenylyl cyclase activation in GT1 gonadotropin-releasing hormone neurosecretory cells. Endocrinology. 1993;132(2):682–8.

    Article  PubMed  CAS  Google Scholar 

  30. Pons S, Torres-Aleman I. Estradiol modulates insulin-like growth factor I receptors and binding proteins in neurons from the hypothalamus. J Neuroendocrinol. 1993;5:267–71.

    Article  PubMed  CAS  Google Scholar 

  31. de Ziegler D, Steingold K, Cedars M, Lu JK, Meldrum DR, Judd HL, et al. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease. J Clin Endocrinol Metab. 1989;68(6):1111–7.

    Article  PubMed  Google Scholar 

  32. Velazquez E, Mendoza S, Hamer T, Sosa F, Glueck C. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism. 1994;43(5):647–54.

    Article  PubMed  CAS  Google Scholar 

  33. Chang RJ, Mandel FP, Wolfsen AR, Judd HL. Circulating levels of plasma adrenocorticotropin in polycystic ovary disease. J Clin Endocrinol Metab. 1982;54(6):1265–7.

    Article  PubMed  CAS  Google Scholar 

  34. Mason HD, Willis DS, Beard RW, Winston RM, Margara R, Franks S. Estradiol production by granulosa cells of normal and polycystic ovaries: relationship to menstrual cycle history and concentrations of gonadotropins and sex steroids in follicular fluid. J Clin Endocrinol Metab. 1994;79(5):1355–60.

    Article  PubMed  CAS  Google Scholar 

  35. Coffler MS, Patel K, Dahan MH, Malcom PJ, Kawashima T, Deutsch R, et al. Evidence for abnormal granulosa cell responsiveness to follicle-stimulating hormone in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88(4):1742–7.

    Article  PubMed  CAS  Google Scholar 

  36. Ovalle F, Azziz R. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril. 2002;77(6):1095–105.

    Article  PubMed  Google Scholar 

  37. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997;18:774–800.

    Article  PubMed  CAS  Google Scholar 

  38. Nestler J, Powers L, Matt D, Steingold KA, Plymate SR, Rittmaster RS, et al. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 1991;72:83–9.

    Article  PubMed  CAS  Google Scholar 

  39. Hales C, Barker D. Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis. Diabetologia. 1992;35: 595–601.

    Article  PubMed  CAS  Google Scholar 

  40. World Health Organization (WHO). Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO Consultation, part 1: diagnosis and classification of diabetes mellitus. Geneva: WHO; 1999.

    Google Scholar 

  41. Talbott E, Zborowski J, Rager J, Boudreaux M, Edmundowicz D, Guzick D. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004;89(11):5454–61.

    Article  PubMed  CAS  Google Scholar 

  42. Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1985;61:946–51.

    Article  PubMed  CAS  Google Scholar 

  43. Dahlgren E, Janson PO, Johansson S, Lapidus L, Oden A. Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand. 1992;71(8):599–604.

    Article  PubMed  CAS  Google Scholar 

  44. Legro R, Kunselman A, Dodson W, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab. 1999;84(1): 165–9.

    Article  PubMed  CAS  Google Scholar 

  45. Hurd WW, Abdel-Rahman MY, Ismail SA, Abdellah MA, Schmotzer CL, Sood A. Comparison of diabetes mellitus and insulin resistance screening methods for women with polycystic ovary syndrome. Fertil Steril. 2011;96(4):1043–7.

    Article  PubMed  CAS  Google Scholar 

  46. Guzick D, Wing R, Smith D, Berga S, Winters S. Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women. Fertil Steril. 1994;61(4):598–604.

    PubMed  CAS  Google Scholar 

  47. Korytkowski M, Mokan M, Horwitz M, Berga S. Metabolic effects of oral contraceptives in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1995;80(11):3327–34.

    Article  PubMed  CAS  Google Scholar 

  48. Cumming D, Yang J, Rebar R, Yen S. Treatment of hirsutism with spironolactone. JAMA. 1982;247(9):1295–8.

    Article  PubMed  CAS  Google Scholar 

  49. De Leo V, Lanzetta D, D’Antona D, la Marca A, Morgante G. Hormonal effects of flutamide in young women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1998;83(1):99–102.

    Article  PubMed  Google Scholar 

  50. Inzucchi S, Maggs D, Spollett G, Page SL, Rife FS, Walton V, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med. 1998;338(13):867–72.

    Article  PubMed  CAS  Google Scholar 

  51. Genazzani A, Battaglia C, Malavasi B, Strucchi C, Tortolani F, Gamba O. Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome. Fertil Steril. 2004;81(1):114–9.

    Article  PubMed  CAS  Google Scholar 

  52. Azziz R, Ehrmann D, Legro R, Whitcomb RW, Hanley R, Fereshetian AG, et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab. 2001;86(4):1626–32.

    Article  PubMed  CAS  Google Scholar 

  53. Nestler J, Daniela J, Evans W, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med. 1998;338:1876–80.

    Article  PubMed  CAS  Google Scholar 

  54. Vandermolen D, Ratts V, Evans W, Stovall D, Kauma S, Nestler J. Metformin increases the ovulatory rate and pregnancy rate from ­clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil Steril. 2001;75:310–5.

    Article  PubMed  CAS  Google Scholar 

  55. Mitwally M, Kuscu N, Yalcinkaya T. High ovulatory rates with use of troglitazone in clomiphene-resistant women with polycystic ovary syndrome. Hum Reprod. 1999;14:2700–3.

    Article  PubMed  CAS  Google Scholar 

  56. Jakubowicz D, Iuorno M, Jakubowicz S, Roberts K, Nestler J. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab. 2002;87(2):524–9.

    Article  PubMed  CAS  Google Scholar 

  57. Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med. 2007;356:551–6.

    Article  PubMed  CAS  Google Scholar 

  58. De Leo V, la Marca A, Petraglia F. Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev. 2003;24(5):633–67.

    Article  PubMed  Google Scholar 

  59. Garber A, Duncan T, Goodman A, Mills D, Rohlf J. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose–response trial. Am J Med. 1997;103:491–7.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors wish to acknowledge Dr. Tammy L. Loucks, who was a contributor to the first edition of this chapter.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Reproductive Medicine Section, Wake Forest Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC, 27153, USA

    Erika B. Johnston-MacAnanny MD & Sarah L. Berga MD

  2. Carolina Conceptions, Raleigh, NC, USA

    John Kyun Park MD, MSc

Authors
  1. Erika B. Johnston-MacAnanny MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John Kyun Park MD, MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sarah L. Berga MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Erika B. Johnston-MacAnanny MD .

Editor information

Editors and Affiliations

  1. Cleveland Clinic, Ob/Gyn & Women's Health Institute, Euclid Ave 9500, Cleveland, 44195, Ohio, USA

    Tommaso Falcone

  2. Duke University Medical Center, Duke University School of Medicine, Department of Obstetrics and Gynecology, Erwin Rd 2301, Durham, 27705, North Carolina, USA

    William W. Hurd

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Johnston-MacAnanny, E.B., Park, J.K., Berga, S.L. (2013). Polycystic Ovary Syndrome. In: Falcone, T., Hurd, W. (eds) Clinical Reproductive Medicine and Surgery. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-6837-0_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-6837-0_8

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-6836-3

  • Online ISBN: 978-1-4614-6837-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation